BioNTech SE

BOVESPA:B1NT34 Stock Report

Market Cap: R$172.8b

BioNTech Management

Management criteria checks 4/4

BioNTech's CEO is Ugur Sahin, appointed in Jan 2008, has a tenure of 16.92 years. total yearly compensation is €3.06M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 17.23% of the company’s shares, worth R$29.77B. The average tenure of the management team and the board of directors is 3.4 years and 4.7 years respectively.

Key information

Ugur Sahin

Chief executive officer

€3.1m

Total compensation

CEO salary percentage22.9%
CEO tenure16.9yrs
CEO ownership17.2%
Management average tenure3.4yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ugur Sahin's remuneration changed compared to BioNTech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-€467m

Jun 30 2024n/an/a

-€504m

Mar 31 2024n/an/a

€113m

Dec 31 2023€3m€700k

€930m

Sep 30 2023n/an/a

€3b

Jun 30 2023n/an/a

€4b

Mar 31 2023n/an/a

€6b

Dec 31 2022€6m€360k

€9b

Sep 30 2022n/an/a

€10b

Jun 30 2022n/an/a

€12b

Mar 31 2022n/an/a

€13b

Dec 31 2021€12m€360k

€10b

Sep 30 2021n/an/a

€7b

Jun 30 2021n/an/a

€4b

Mar 31 2021n/an/a

€1b

Dec 31 2020€17m€360k

€15m

Sep 30 2020n/an/a

-€410m

Jun 30 2020n/an/a

-€230m

Mar 31 2020n/an/a

-€192m

Dec 31 2019€7m€311k

-€179m

Sep 30 2019n/an/a

-€122m

Jun 30 2019n/an/a

-€116m

Mar 31 2019n/an/a

-€77m

Dec 31 2018€653k€210k

-€48m

Compensation vs Market: Ugur's total compensation ($USD3.18M) is below average for companies of similar size in the BR market ($USD5.73M).

Compensation vs Earnings: Ugur's compensation has been consistent with company performance over the past year.

CEO

Ugur Sahin (59 yo)

16.9yrs

Tenure

€3,056,000

Compensation

Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...

Leadership Team

NamePositionTenureCompensationOwnership
Ugur Sahin
Co-Founder16.9yrs€3.06m17.23%
R$ 29.8b
Ozlem Tureci
Co-Founder6.9yrs€814.00k0.38%
R$ 658.4m
Jens Holstein
CFO & Member of Management Board3.4yrs€1.32m0.00068%
R$ 1.2m
Sierk Poetting
MD, COO & Member of Management Board10.9yrs€821.00k0.31%
R$ 544.2m
Ryan Richardson
Chief Strategy Officer4.9yrs€1.41m0.0061%
R$ 10.6m
James Timothy Ryan
Chief Legal & Business Officer & Member of the Management Board1.3yrs€848.00kno data
Sean Marett
Executive Officerless than a year€133.00k0.34%
R$ 587.8m
Lisa Birringer
Senior Vice President of Global Financial Reporting & Accountingless than a yearno datano data
Zach Taylor
Senior Vice President of Corporate Development & Strategyless than a yearno datano data
Katalin Kariko
Senior VP & External Consultant for RNA Protein Replacement Therapiesno datano datano data
Oliver Henning
Senior Vice President of Operationsno datano datano data
Sebastian Kreiter
Senior Vice President of Immunotherapy & Preclinical Researchno datano datano data

3.4yrs

Average Tenure

57yo

Average Age

Experienced Management: B1NT34's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rudolf Staudigl
Supervisory Board Member2.5yrs€90.00k0.00017%
R$ 293.8k
Ulrich Wandschneider
Independent Deputy Chairman Supervisory Board6.9yrs€114.00kno data
Michael Motschmann
Independent Supervisory Board Member16.9yrs€80.00kno data
Helmut Jeggle
Independent Supervisory Board Chairman16.9yrs€226.00k0.14%
R$ 239.6m
Nicola Blackwood
Member of Supervisory Board1.6yrs€46.00kno data
Anja Morawietz
Supervisory Board Member2.5yrs€105.00k0.00010%
R$ 172.8k

4.7yrs

Average Tenure

58.5yo

Average Age

Experienced Board: B1NT34's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 10:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioNTech SE is covered by 29 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Zhiqiang ShuBerenberg
Etzer DaroutBMO Capital Markets Equity Research